Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Camrelizumab

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Camrelizumab on our secure patient portal to submit your prescription, upload documents and track your approval status.

Camrelizumab

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Camrelizumab
Generic Name (API): Camrelizumab
Dosage Form & Strength: 200 mg
Route: Intravenous (IV) infusion
Drug Class: Humanised IgG4 anti-PD-1 monoclonal antibody (immune checkpoint inhibitor)

Manufacturer / Innovator:

Suzhou Suncadia Biopharmaceuticals Co., Ltd. (Jiangsu Hengrui Pharmaceuticals)

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Camrelizumab Used For?

Camrelizumab is a PD-1 immunotherapy given as a drip, used in China for liver, lung, oesophageal, nasopharyngeal (back-of-the-nose) and cervical cancers. Jiangsu Hengrui Pharmaceuticals developed it, and its subsidiary Suzhou Suncadia Biopharmaceuticals Co., Ltd. holds the licence and makes it under the brand name AiRuiKa® (艾瑞卡). During development it was known as SHR-1210.

China's National Medical Products Administration (NMPA) first approved it in May 2019, for classical Hodgkin lymphoma that had come back after at least two lines of chemotherapy. Hengrui's July 2026 approval notice lists these current uses:

  • Liver cancer (hepatocellular carcinoma): first-line, together with apatinib tablets (also called rivoceranib), when the tumour cannot be removed or has spread; and on its own for advanced liver cancer after earlier targeted tablets and/or platinum-based chemotherapy
  • Non-squamous non-small cell lung cancer (NSCLC): first-line, with pemetrexed and carboplatin, provided tests show neither an EGFR mutation nor an ALK rearrangement
  • Squamous NSCLC: first-line, with paclitaxel and carboplatin
  • Oesophageal squamous cell cancer: first-line with paclitaxel and cisplatin, or on its own after first-line chemotherapy has stopped working
  • Nasopharyngeal cancer: first-line with cisplatin and gemcitabine for recurrent or metastatic disease, or on its own after two or more lines of chemotherapy
  • Cervical cancer: with famitinib capsules, either first-line for recurrent or metastatic disease that tests PD-L1 positive (CPS 1 or more), approved in July 2026, or after platinum chemotherapy in women who have not had an anti-VEGF antibody

The right use depends on the exact cancer, its stage and test results, so the oncologist decides whether a patient fits. You can see the other cancer medicines we help import on our oncology page.

How It Works

T cells, the immune cells that hunt down tumours, carry a switch called PD-1. Many cancers flip this switch to make T cells stand down. This medicine is a humanised IgG4 monoclonal antibody that binds PD-1 and blocks it from meeting its partners PD-L1 and PD-L2, so the T cells can go back to work against the cancer. Lab studies also show a weak binding to VEGFR2, which may be linked to a skin side effect that is typical of this antibody (described under Warnings).

What the Trials Showed

  • CARES-310 (liver cancer, first-line): 543 patients across 13 countries and regions. With apatinib, median survival was 22.1 months against 15.2 months on a comparison tablet treatment at the planned analysis, and the final analysis published in 2025 reported 23.8 months. Tumours shrank in 25.4% versus 5.9%.
  • CameL (non-squamous lung cancer): 412 patients. Adding it to pemetrexed and carboplatin extended the median time before the cancer grew from 8.25 to 11.27 months, and median survival from 20.47 to 27.86 months.
  • ESCORT-1st (oesophageal cancer, first-line): 596 patients. Median survival was 15.3 months with paclitaxel and cisplatin plus the antibody, compared with 12.0 months with placebo plus the same chemotherapy.
  • Cervical cancer, first-line (study SHR-1210-III-329): 443 patients. In the PD-L1-positive group, the combination with famitinib gave a median survival of 35.8 months against 23.6 months with platinum chemotherapy.

Recommended Dosage

Each vial holds 200 mg of powder, which is dissolved and diluted by the hospital pharmacy before use. As per the Chinese label:

  • On its own (oesophageal cancer after chemotherapy, nasopharyngeal cancer): 200 mg as an intravenous drip every 2 weeks
  • Liver cancer on its own: 3 mg per kg every 3 weeks
  • With chemotherapy (lung, first-line oesophageal and first-line nasopharyngeal cancer): 200 mg every 3 weeks, given first, with chemotherapy started at least 30 minutes later
  • First-line liver cancer: 200 mg every 2 weeks, plus apatinib 250 mg by mouth once a day after a meal
  • Cervical cancer: in the studies behind these approvals it was given at 200 mg every 3 weeks alongside daily famitinib
  • Each infusion takes roughly half an hour to an hour and must not be given as a rapid injection. The dose is not raised or lowered; it is paused or stopped if side effects need it.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Skin blood-vessel growths (RCEP): the side effect most specific to this antibody is reactive cutaneous capillary endothelial proliferation, small red, raised spots made of tiny blood vessels. In the label's pooled data from 2,011 patients treated alone or with chemotherapy, 76.0% developed them, nearly all grade 1 or 2 (grade 3 in 1.1%). They usually appear in the first month or so and can bleed if knocked. They were far less frequent (27.8%) when the drip was combined with apatinib or famitinib. Tell the team about spots that bleed, get infected, or appear in the mouth, nose or eyes.

Immune-related side effects can affect almost any organ, during treatment or months later. Figures from the same 2,011 patients:

  • Thyroid: an underactive thyroid in 22.8% and an overactive thyroid in 7.8%. Thyroid blood tests are checked regularly.
  • Liver: immune hepatitis in 9.1%, so liver tests are repeated before each cycle.
  • Lungs: pneumonitis in 5.3%, including some deaths (0.5%). Report a new cough or breathlessness straight away.
  • Kidneys, bowel and skin: nephritis in 2.6%, diarrhoea or colitis in 1.8% and immune skin reactions in 9.6%. Severe skin reactions (SJS/TEN) have been reported after marketing.
  • Rarer problems: raised blood sugar or diabetes, adrenal or pituitary problems, pancreatitis, low platelets and myocarditis (heart muscle inflammation).
  • Infusion reactions: 1.1%, mostly mild.

Common side effects when used alone (1,181 patients): besides the skin spots, raised liver enzymes (AST 20.3%, ALT 18.5%), underactive thyroid (17.8%), tiredness (15.6%), anaemia (15.0%), protein in the urine (11.9%) and fever (10.9%). With apatinib or famitinib, raised liver enzymes, low platelets, high blood pressure and diarrhoea were more frequent.

Who should not use it: anyone allergic to the antibody or its other ingredients. Safety in under-18s has not been established, and it is not advised for people with moderate or severe kidney problems because data are lacking. Pregnancy: it should be used only when the expected gain for the mother justifies the possible harm to the baby. Reliable birth control is needed while on treatment and for 2 months after the final infusion, and mothers should not breastfeed during that time either.

How to Access Camrelizumab in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Camrelizumab to India?

It can be supplied only for a named patient, requested by the patient or the treating hospital, under India's rules for importing unapproved medicines. Please keep these ready:

  • A prescription from a medical oncologist, naming the cancer and the planned regimen
  • Biopsy and scan reports, with test results that the chosen use depends on (for example EGFR/ALK for lung cancer, PD-L1 for cervical cancer)
  • A summary of earlier treatment, if the request is for a later-line use
  • Government-issued photo ID of the patient

How is the order confirmed?

Once our team has checked the prescription and reports and, where required, the import permit has been issued.

Is Camrelizumab available in India?

No. CDSCO has not approved it, and we found no Indian approval, expert-committee recommendation or launch. It is not approved by the US FDA or in the European Union either.

Doctors can request it through the Named Patient Program (NPP), which allows one patient to import a medicine that is not registered in India on a prescription. For cervical cancer, its label partner famitinib capsules can be arranged through the same route, and we also handle another China-approved PD-1 antibody, sintilimab.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for the vials to be stored and transported at 2°C to 8°C, protected from light and never frozen, so they travel under temperature-controlled shipping with a temperature record for the whole journey. Each 200 mg vial is a single dose for most patients, so we usually plan supply around the two- or three-weekly infusion calendar the oncologist has set. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Because the vials need a refrigerator from the factory to the infusion room, every delivery is planned around the hospital's cycle date. Once the oncologist's prescription and the import papers are in place, we can serve the cities below and many others.

Delhi

Hospitals in Delhi treating liver and lung cancer can receive the refrigerated vials quickly, since every shipment is dispatched from New Delhi.

Mumbai

Oncologists in Mumbai can email the prescription and biopsy report, and we confirm the paperwork before the next infusion is booked.

Bangalore

For lung cancer patients in Bangalore on a three-weekly chemotherapy plan, the vial is timed to arrive a day or two before each cycle.

Chennai

Liver cancer teams in Chennai using the apatinib combination on a two-weekly schedule can receive regular cold-chain deliveries.

Hyderabad

Patients in Hyderabad receive a written quote and a delivery plan before anything is ordered.

Kolkata

For hospitals in Kolkata and the north-eastern states, we share the courier and temperature-log details with the family before each refrigerated parcel leaves Delhi.

Pune

Cervical cancer patients in Pune whose tumour tests PD-L1 positive can have the request and supporting reports reviewed by our team.

Ahmedabad

Doctors in Ahmedabad can start a request for oesophageal cancer patients by sharing the scan reports and treatment history.

Guwahati

Head and neck cancer centres in Guwahati can request supply for nasopharyngeal cancer patients, with delivery planned around the longer transit to the north-east.

Chandigarh

Patients from Punjab, Haryana and Himachal Pradesh can have the medicine delivered to their cancer centre in Chandigarh.

Lucknow

Hospitals in Lucknow serving patients from across Uttar Pradesh can receive temperature-logged deliveries for each cycle.

Kochi

Cancer centres in Kochi and Thiruvananthapuram can receive the powder vials for reconstitution by their own oncology pharmacists.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 19 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP